|
|
Article: Collegium Pharmaceutical Announces Successful Completion of Proof of Concept Clinical Trial for Novel Combination Allergic Rhinitis Product.
- Article from:
- Business Wire
- Article date:
- March 5, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CUMBERLAND, R.I. -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the results of its randomized, placebo controlled, multi-center "Proof of Concept" (POC) trial that was initiated to investigate the potential for its novel, 'once a day' combination product for the treatment of seasonal allergic rhinitis (SAR) to meet its desired endpoints. The approved commercially available components of the product candidate were used for this trial.
After meeting with the FDA and receiving guidance on the basis of approval, Collegium has established a clinical plan aimed at achieving regulatory approval for its patent protected modified ...